Motor neuron disease in 2017

Progress towards therapy in motor neuron disease

In 2017, dramatic advances have been made in the treatment of motor neuron diseases. New therapies have been approved for spinal muscular atrophy and amyotrophic lateral sclerosis, and a host of other therapies that are currently under development are showing promising results.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Therapeutic advances across the motor neuron disease landscape.


  1. 1

    Eisen, A. et al. Cortical influences drive amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 88, 917–924 (2017).

    Article  Google Scholar 

  2. 2

    Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017).

    CAS  Article  Google Scholar 

  3. 3

    The Writing Group. Safety and efficacy of edaravone inwell defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505–512 (2017).

  4. 4

    Mora, J. S., Barbeito, L. & Hermine, O. Masitinib as an add-on therapy to riluzole is beneficial in the treatment of amyotrophic lateral sclerosis (ALS) with acceptable tolerability: results from a randomized controlled phase 3 trial. European Network to Cure ALS (ENCALS) (2017).

  5. 5

    Meininger, V. et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 16, 208–216 (2017).

    CAS  Article  Google Scholar 

  6. 6

    van Eijk, R. P. A. et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry (2017).

    Article  Google Scholar 

  7. 7

    McLaughlin, R. L. et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat. Commun. 8, 14774 (2017).

    CAS  Article  Google Scholar 

  8. 8

    Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet 377, 942–955 (2011).

    CAS  Article  Google Scholar 

  9. 9

    Turner, M. R. & Kiernan, M. C. The standard of care in amyotrophic lateral sclerosis: a centralised multidisciplinary clinic encounter sets a new benchmark for a uniquely challenging neurodegenerative disorder. J. Neurol. Neurosurg. Psychiatry 86, 481–482 (2015).

    Article  Google Scholar 

  10. 10

    van Eijk, R. P. A., et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 89, 1915–1922 (2017).

    Article  Google Scholar 

Download references


M.C.K. is supported by funding from the National Health and Medical Research Council of Australia (Program Grant #1037746).

Author information



Corresponding author

Correspondence to Matthew C. Kiernan.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kiernan, M. Progress towards therapy in motor neuron disease. Nat Rev Neurol 14, 65–66 (2018).

Download citation

Further reading


Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing